EUYI is a clinical-value-driven enterprise specializing in the R&D, manufacturing, and commercialization of innovative In Vitro Diagnostic (IVD) reagents, equipment, and cross-disciplinary products that integrate biotechnology with Artificial Intelligence. We are committed to providing high-performance, reliable, and highly automated diagnostic solutions, with a comprehensive portfolio encompassing reagents, consumables, hardware, and AI software.

R&D and Industrial Strength

· Top-tier R&D Team: Driven by independent innovation, our team comprises top-tier scientists and industry experts, with full-chain capabilities ranging from core technology development to large-scale industrialization.

· Deep Industry-Academia-Research Collaboration: We maintain strategic partnerships with top-tier research teams from institutions such as the University of Science and Technology of China (USTC), Central South University and the Chinese University of Hong Kong, undertaking major strategic R&D projects.

· Integrated Supply Chain: By actively integrating upstream and downstream resources, EUYI ensures supply chain security and rigorous quality control. This integrated approach allows us to break technical barriers, optimize cost-efficiency, and compete effectively on the global stage.

Core Product Pipeline & Achievements

Benchmarking against international standards, EUYI focuses on cutting-edge frontiers and has achieved significant commercial success:

Phase I: Delivering Leading Screening Solutions

As a key international supplier, EUYI provides a comprehensive "HPV Nucleic Acid + Cytology + Dual Staining" solution for large-scale cervical cancer screening programs worldwide. Our non-invasive bladder cancer screening product is currently on the market, with supporting AI-assisted interpretation software to be launched shortly.

Genetic Disease Testing: We have launched a highly stable, global-standard genetic testing solution for Thalassemia, which has been successfully deployed in major international testing projects.

Phase II: Driving the Revolutionary Fusion of Biotech and AI

· AI Liquid Biopsy: Breaking through traditional technical bottlenecks, we utilize cell sorting to extend into personalized companion diagnostics (CDx) and biotherapy, achieving a full-link innovation of "Detection–Companion Diagnostics–Treatment".

· At-Home NAT with AI Interpretation: EUYI is developing at-home nucleic acid testing products for HIV. This fills a critical market gap and disrupts traditional institutional testing models, establishing a new paradigm for the industry.

Future Outlook

EUYI’s current product portfolio has already gained prominence in the international medical diagnostics market, competing alongside world-renowned enterprises. Looking ahead, we will continue to release disruptive innovations, leveraging our world-class technical expertise to fulfill our commitment: "Right Diagnostics. Real Clinical Value”